Reslizumab and mepolizumab for moderate-to-severe poorly controlled asthma: an indirect comparison meta-analysis

Immunotherapy. 2019 Dec;11(17):1491-1505. doi: 10.2217/imt-2019-0113. Epub 2019 Nov 5.

Abstract

Aim: A systematic literature review and network meta-analysis assessed the efficacy and safety of reslizumab 3.0 mg/kg and mepolizumab 100 mg. Materials & methods: Eligible studies evaluated reslizumab and mepolizumab in patients with inadequately-controlled severe eosinophilic asthma. Using a Bayesian network meta-analysis, 95% credible intervals and posterior probabilities were reported. Results: Of 19 indirect efficacy comparisons performed in base-case (Global Initiative for Asthma 4/5 patients with ≥2 exacerbations in the previous year) and overall populations, significant differences favoring reslizumab were observed for severe exacerbations, FEV1 at 4 weeks and eosinophil counts at 4, 16 and 24 weeks, with no other significant differences including risk of adverse events. Conclusion: Indirect comparison of reslizumab and mepolizumab largely showed no significant differences in efficacy or safety.

Keywords: eosinophilic asthma; indirect comparison; mepolizumab; network meta-analysis; reslizumab.

Publication types

  • Comparative Study
  • Meta-Analysis
  • Research Support, Non-U.S. Gov't
  • Systematic Review

MeSH terms

  • Adult
  • Antibodies, Monoclonal, Humanized / adverse effects
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Asthma / blood
  • Asthma / drug therapy*
  • Asthma / physiopathology
  • Bayes Theorem
  • Eosinophils / drug effects
  • Forced Expiratory Volume / drug effects
  • Humans
  • Middle Aged

Substances

  • Antibodies, Monoclonal, Humanized
  • reslizumab
  • mepolizumab